SCHEMBL3968096

SCHEMBL3968096

COc1cccc([C@]2(Cc3cccc(Cl)c3)C(=O)Nc3cc(Cl)ccc32)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 4/20 1.00
TP53 P04637 4/20 1.00
CDYL Q9Y232 2/20 0.44
CBX7 O95931 1/20 0.44
MAOB P27338 1/20 0.43
SCN9A Q15858 1/20 0.41
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
HTR1A P08908 1/20 0.40
DRD1 P21728 1/20 0.40
HTR2A P28223 1/20 0.40
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40
ADAMTS5 Q9UNA0 2/20 0.40
MAPT P10636 2/20 0.39
PGR P06401 2/20 0.38
TSHR P16473 1/20 0.38
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968099 1.00 MDM2 (1.00) MDM2TP53CDYLCBX7MAOB
SCHEMBL3964752 0.97 MDM2 (0.94) MDM2TP53CDYLCBX7MAOB
SCHEMBL3968204 0.94 MDM2 (0.88) MDM2TP53CDYLCBX7MAOB
SCHEMBL3969641 0.92 MDM2 (0.86) MDM2TP53CDYLCBX7MAOB
SCHEMBL3964604 0.92 MDM2 (0.86) MDM2TP53CDYLCBX7MAOB
SCHEMBL3966369 0.92 MDM2 (0.85) MDM2TP53CDYLCBX7MAOB
SCHEMBL3969587 0.92 MDM2 (0.85) MDM2TP53CDYLCBX7MAOB
SCHEMBL3968763 0.91 TP53 (0.84) MDM2TP53CDYLCBX7MAOB
SCHEMBL3973955 0.89 MDM2 (0.80) MDM2TP53CDYLCBX7SCN9A
SCHEMBL3962174 0.89 MDM2 (0.79) MDM2TP53CDYLCBX7MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 MDM2 759/4885TP53 96/4885CDYL 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.